SCHEDULE: Foundation Fighting Blindness Exits Opus Genetics Stake

Foundation Fighting Blindness RD Fund and Foundation Fighting Blindness, Inc. have reduced their stake in Opus Genetics, Inc. below the 5% reporting threshold.

Summary

• The Foundation Fighting Blindness RD Fund and Foundation Fighting Blindness, Inc. sold shares of Opus Genetics, Inc. on May 18, 2026.
• Following the transaction, the reporting persons hold 3,792,171 shares, representing 4.66% of the outstanding common stock.
• This filing serves as an exit filing, as the reporting persons no longer beneficially own more than 5% of the issuer's common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a standard regulatory disclosure regarding a change in ownership status rather than a fundamental shift in the company's operational health.

Positives

• The reporting entities have successfully liquidated a portion of their position, providing liquidity to the funds.

Negatives

• The reduction in ownership by a significant institutional holder may be perceived as a lack of long-term conviction in the issuer's immediate growth prospects.

Risks

• The sale of a significant block of shares by a major institutional investor could exert downward pressure on the stock price.

Future Outlook

The reporting persons expect this to be the final amendment to their Schedule 13D, as they have fallen below the 5% ownership threshold required for reporting.

Management Comments

• The reporting persons certify that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that institutional divestment below the 5% threshold is a common occurrence in the biotech sector as funds rebalance portfolios or reach the end of their investment horizon in specific clinical-stage companies.

Comparison to Industry Standards

• The exit filing is consistent with standard regulatory compliance for institutional investors reducing positions in small-cap biotech firms.
• The 4.66% remaining stake is a standard 'passive' holding level for non-insider institutional investors.

Stakeholder Impact

• Shareholders may see increased liquidity in the stock due to the sale of the block.
• The reduction in institutional ownership may signal a change in the long-term investment strategy of the Foundation.

Next Steps

• Termination of reporting obligations under Section 13(d) of the Exchange Act.

Key Dates

Keywords

Opus Genetics, Schedule 13D, Foundation Fighting Blindness, Beneficial Ownership, Exit Filing, Equity Sale